Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) EPS (Basic) (2016 - 2025)

Plus Therapeutics has reported EPS (Basic) over the past 15 years, most recently at -$0.07 for Q4 2025.

  • Quarterly EPS (Basic) rose 85.01% to -$0.07 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.21 through Dec 2025, up 41.26% year-over-year, with the annual reading at -$0.29 for FY2025, 85.13% up from the prior year.
  • EPS (Basic) was -$0.07 for Q4 2025 at Plus Therapeutics, down from -$0.04 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $0.02 in Q2 2025 and troughed at -$3.56 in Q2 2022.
  • The 5-year median for EPS (Basic) is -$0.49 (2024), against an average of -$0.92.
  • Year-over-year, EPS (Basic) plummeted 1324.0% in 2022 and then surged 104.44% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.28 in 2021, then tumbled by 742.86% to -$2.36 in 2022, then soared by 70.34% to -$0.7 in 2023, then skyrocketed by 30.0% to -$0.49 in 2024, then skyrocketed by 85.01% to -$0.07 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's EPS (Basic) are -$0.07 (Q4 2025), -$0.04 (Q3 2025), and $0.02 (Q2 2025).